Your browser is no longer supported. Please, upgrade your browser.
GILD Gilead Sciences, Inc. daily Stock Chart
Gilead Sciences, Inc.
IndexS&P 500 P/E6.82 EPS (ttm)9.46 Insider Own0.40% Shs Outstand1.31B Perf Week0.42%
Market Cap84.55B Forward P/E8.68 EPS next Y7.43 Insider Trans-8.82% Shs Float1.30B Perf Month-5.95%
Income12.64B PEG- EPS next Q2.11 Inst Own77.40% Short Float0.82% Perf Quarter-8.51%
Sales29.10B P/S2.91 EPS this Y-16.50% Inst Trans-1.37% Short Ratio1.35 Perf Half Y-14.34%
Book/sh15.63 P/B4.13 EPS next Y-9.45% ROA22.80% Target Price78.59 Perf Year-24.38%
Cash/sh10.77 P/C5.99 EPS next 5Y-5.60% ROE70.50% 52W Range63.88 - 88.85 Perf YTD-9.93%
Dividend2.08 P/FCF9.32 EPS past 5Y41.20% ROI31.00% 52W High-27.41% Beta1.24
Dividend %3.22% Quick Ratio2.40 Sales past 5Y29.40% Gross Margin86.20% 52W Low0.97% ATR0.80
Employees9000 Current Ratio2.60 Sales Q/Q-16.50% Oper. Margin57.60% RSI (14)35.69 Volatility0.82% 1.20%
OptionableYes Debt/Eq0.00 EPS Q/Q-18.90% Profit Margin43.40% Rel Volume0.51 Prev Close64.56
ShortableYes LT Debt/Eq1.29 EarningsMay 02 AMC Payout20.20% Avg Volume7.87M Price64.50
Recom2.30 SMA20-2.69% SMA50-3.45% SMA200-11.07% Volume4,021,663 Change-0.09%
Mar-09-17Resumed UBS Neutral $118 → $72
Feb-08-17Downgrade Citigroup Buy → Neutral
Nov-14-16Initiated Stifel Buy $100
Nov-08-16Initiated Mizuho Buy $88
Nov-02-16Reiterated RBC Capital Mkts Outperform $95 → $90
Oct-25-16Reiterated Jefferies Buy $93 → $95
Oct-03-16Reiterated RBC Capital Mkts Outperform $105 → $95
Sep-27-16Downgrade Leerink Partners Outperform → Mkt Perform $112 → $94
Sep-12-16Initiated Berenberg Buy $112
Sep-06-16Upgrade Jefferies Hold → Buy
Jul-29-16Downgrade Argus Buy → Hold
Jul-26-16Reiterated RBC Capital Mkts Outperform $120 → $105
Jul-26-16Downgrade Needham Buy → Hold
Jun-01-16Initiated Gabelli & Co Buy $109
Apr-29-16Reiterated UBS Buy $130 → $118
Apr-29-16Downgrade Maxim Group Buy → Hold
Mar-16-16Reiterated Leerink Partners Outperform $130 → $127
Feb-25-16Initiated Citigroup Buy $110
Feb-12-16Reiterated Maxim Group Buy $137 → $115
Feb-03-16Reiterated RBC Capital Mkts Outperform $130 → $120
May-27-17 08:00AM  Which Biotechs Benefit Most Under Trump's Tax Reform Vision? Investor's Business Daily
May-26-17 06:06PM  TAF-Based Regimens Could Boost Gilead Sciences Revenue Growth Market Realist
05:45PM  Gilead Sciences CFO named Financial Woman of the Year American City Business Journals
04:23PM  Genvoya Could Drive Gilead Sciences Revenue Growth in 2017 Market Realist
10:49AM  1 Underdog Stock I'm Watching Motley Fool
08:17AM  3 Value Stocks for Daring Investors Motley Fool
May-25-17 12:23PM  These 5 Healthcare Stocks Are Undervalued Forbes
09:50AM  Short Sellers Raise the Stakes in Major Biotechs 24/7 Wall St.
May-24-17 04:41PM  3 Reasons Gilead Sciences, Inc. Is a Better Dividend Stock Than Amgen, Inc. Motley Fool
02:29PM  Inovio Pharmaceuticals Stock Soars on Encouraging HIV Vaccine Readout Motley Fool
08:34AM  Is The Worst Behind Gilead Sciences? Motley Fool
May-23-17 02:06PM  Valeant and Gilead: Beaten Down Bargains or Truly Terrible? Motley Fool
May-22-17 02:30PM  Amgen's Woes: It Could Always Be Worse! Investopedia
May-19-17 06:46PM  Cramer's lightning round: I've got a message for the struggling Gilead Sciences CNBC
01:09PM  5 Reasons Big Biotech Could Gain 25%-30%
12:02PM  Why Stay Bullish On Gilead
09:06AM  Revisiting Bristol-Myers Squibbs Virology in 1Q17 Market Realist
08:00AM  Top 5 Biotech Stocks for 2017 Investopedia
May-18-17 07:37AM  A Doomed Trump Presidency Would Be a Terrifying Development for Pharmaceutical Stocks Motley Fool
May-17-17 03:42PM  3 Dividend Stocks You Haven't Thought Of Motley Fool
May-16-17 03:42PM  3 Best Dividend Stocks in Biotech Motley Fool
May-15-17 04:55PM  Gilead's last chronic HIV drug and what it plans to do now American City Business Journals
08:15AM  Blog Coverage: Ardelyx Reports Successful Trial Results for Treatment of Patients with Irritable Bowel Syndrome with Constipation Accesswire
May-14-17 09:03AM  Better Buy: Gilead Sciences, Inc. vs. Amgen Inc. Motley Fool
May-12-17 05:00PM  Johnson & Johnson Analyst Day Yahoo Finance Video
May-11-17 09:17AM  3 Top Biotech Stocks For May Motley Fool
May-10-17 10:40AM  Major Biotech Short Interest Remains Mixed 24/7 Wall St.
08:05AM  Why Gilead Sciences Stock Lagged Behind Other Biotechs in April Motley Fool
May-09-17 03:29PM  Here's Why Diplomat Pharmacy Inc. Is Rising Today Motley Fool
10:12AM  I Still Can't Believe Gilead Sciences, Inc. Spent $14.8 Billion on Shareholder Rewards Motley Fool
08:21AM  3 Stocks That Generate Tons of Cash Motley Fool
May-08-17 09:12AM  Gilead Sciences, Inc. breached its 50 day moving average in a Bearish Manner : GILD-US : May 8, 2017 Capital Cube
May-07-17 10:05AM  Earnings Preview: What To Expect From Valeant Pharmaceuticals On Tuesday Forbes
May-05-17 06:49PM  Cramer's lightning round: This beaten-down biotech is a value trap CNBC
02:05PM  Wall Street Ratings for Gilead Sciences after 1Q17 Earnings Market Realist
12:34PM  Gilead Sciences Expects Modest Revenue Performance in 2017 Market Realist
10:49AM  Better Buy: Gilead Sciences, Inc. vs. Johnson & Johnson Motley Fool
May-04-17 05:00PM  Gilead Sciences to Present at the Bank of America Merrill Lynch Healthcare Conference on Thursday, May 18 Business Wire
04:21PM  A Big, New Threat to Gilead Sciences Is Coming Motley Fool
02:05PM  Edited Transcript of GILD earnings conference call or presentation 2-May-17 8:30pm GMT Thomson Reuters StreetEvents
11:53AM  Analysts On Gilead: We Think They're Mobilizing For A Deal Benzinga
10:38AM  [$$] Did Gilead Cut Buybacks for Acquisition?
09:44AM  Multiple Provinces and Territories Demonstrate Leadership in the Treatment of HIV/AIDS by Providing Access to GENVOYA® PR Newswire
09:44AM  Multiple Provinces and Territories Demonstrate Leadership in the Treatment of HIV/AIDS by Providing Access to GENVOYA® CNW Group
09:26AM  Québec Demonstrates Leadership in the Treatment of HIV/AIDS by Providing Access to GENVOYA® CNW Group
May-03-17 06:47PM  No Gilead Sciences M&A Yet, but CEO Offers Hint of Deals to Come
04:24PM  Did Gilead Just Provide Some 'Incyte' Into A Potential Deal? Investor's Business Daily
02:58PM  Gilead Sciences Posts Mixed Q1 Results: ETFs in Focus Zacks
02:43PM  After Gilead Earnings, Buy These Biotech Stocks Zacks
02:20PM  Gilead Sciences' 5-Point Plan to Turn Things Around Motley Fool
01:27PM  Tech, biotech, & small-caps in the Blitz CNBC Videos
11:46AM  Gilead's Q1 Fails To Impress, But Strength Of Pipeline Not Reflected In Current Share Price Benzinga
11:46AM  Gilead Sciences: Well, At Least the Bottom Hasn't Fallen Out
10:25AM  Gilead (GILD) Beats on Q1 Earnings, Revenues Miss Estimates Zacks
10:20AM  One of the most popular stocks in America has lost almost half its value in 2 years Business Insider
09:44AM  Gilead Sciences: But What About Its Valuation?!?!
09:30AM  Alphabet, Boston Beer, Apple and Gilead Sciences highlighted as Zacks Bull and Bear of the Day Zacks
09:10AM  In Light Of Negative Sentiment, Gilead's Q1 Results Weren't So Bad Benzinga
07:54AM  Early movers: AAPL, ADP, EL, GRMN, HUM, DLPH, YUM, MDLZ & more CNBC
07:22AM  Biotech Stock Roundup: Amgen, Gilead, Celgene Q1 Earnings, Sunesis Down on Vosaroxin Update Zacks
06:00AM  GILD Just Became Big Pharma Investopedia
May-02-17 06:24PM  Gilead Sciences Inc.'s Revenue and Earnings Continue to Fall on Declining HCV Sales Motley Fool
05:54PM  Apple Sells Fewer iPhones, Gilead Misses Sales Zacks
05:48PM  Gilead (GILD) Misses Q1 Earnings and Revenue Estimates, Stock Drops Zacks
05:40PM  Gilead sinks on earnings in the after hours CNBC Videos
05:31PM  Gilead Topples On Consensus-Lagging Q1 As Hepatitis C Drug Sales Plummet Investor's Business Daily
04:56PM  Gilead Sciences: Another Earnings Release, Another Disappointment
04:27PM  Dow's Pfizer Tops Earnings Views, But Sales Come Up Short Investor's Business Daily
04:13PM  Gilead Stock Drops Following Earnings Miss
04:10PM  Gilead Sciences shares fall after earnings miss MarketWatch
04:01PM  Gilead Sciences Announces First Quarter 2017 Financial Results Business Wire
07:18AM  Gilead earnings: Lowered expectations could help when company reports first-quarter results MarketWatch
05:58AM  European Stocks Edge Higher; U.S. Tech Sector Earnings In Focus
03:07AM  European Stocks Called Higher After U.S. Tech Earnings Lift Asia Markets
May-01-17 12:05PM  Merck: Analysts Ratings and Recommendations Market Realist
10:56AM  Earnings Preview: Q1 Results From Pfizer, Merck, And Gilead Sciences This Week Benzinga
10:08AM  Gilead Sciences: Fool Me Once
09:40AM  Drug Stocks Q1 Earnings Slated for May 2: MRK, PFE & GILD Zacks
09:30AM  Apple, Facebook and Gilead Sciences are part of Zacks Earnings Preview Zacks
08:42AM  3 Big Drugmakers That Could Make Billions Under Trump's Tax Plan Motley Fool
07:00AM  Nova Scotia Lists EPCLUSA on Public Drug Plan to Treat All Six Genotypes of Chronic Hepatitis C Infection CNW Group
01:00AM  Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views
Apr-30-17 11:01AM  3 Things to Watch With Gilead Sciences, Inc. Q1 Results Motley Fool
Apr-28-17 04:54PM  Gilead Sciences, Inc. Value Analysis (NASDAQ:GILD) : April 28, 2017 Capital Cube
04:38PM  Bristol-Myers Beats Gilead, Merck To Key Approvals In China, Europe Investor's Business Daily
02:44PM  The Tech Sector's Strong Earnings Power Zacks
08:55AM  Biotech Surge: How To Survive In A Volatile Market Investor's Business Daily
08:45AM  Why Gilead (GILD) Might Surprise This Earnings Season Zacks
Apr-27-17 05:16PM  Mixed bag for biotech earnings CNBC Videos
02:58PM  Gilead, NetApp, First Solar Could Profit Most on Trump's Tax Plan
10:41AM  1 Dividend Stock That Could Double Your Money Motley Fool
08:36AM  Gilead Sciences, Inc. breached its 50 day moving average in a Bullish Manner : GILD-US : April 27, 2017 Capital Cube
07:39AM  Biogen Reports Strong Revenue Growth in 1Q17 Market Realist
Apr-26-17 10:35AM  Gilead Sciences: Is the Bottom In?
08:18AM  Biotech Stock Roundup: Biogen Gains on Strong Q1, NASH Data on Gilead Drug Zacks
Apr-25-17 04:00PM  Gilead (GILD) Q1 Earnings: Stock Likely to Beat Estimates? Zacks
01:39PM  Gilead Sciences: NASH BridgesTo What?
08:43AM  3 Stocks Could Double Their Dividends -- But Shouldn't Motley Fool
06:05AM  America's 12 Most Charitable Companies Motley Fool
Apr-24-17 01:02PM  Better Buy: Gilead Sciences vs. Celgene Motley Fool
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and the Middle East. The company's products include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis C virus and hepatitis B virus; hematology/oncology; cardiovascular; and inflammation/respiratory diseases. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cogan John FrancisDirectorMay 09Option Exercise20.7115,000310,57562,562May 11 06:14 PM
Cogan John FrancisDirectorMay 09Sale67.259,943668,66752,619May 11 06:14 PM
MARTIN JOHN CExecutive ChairmanMay 01Option Exercise21.5873,3331,582,1593,199,969May 03 05:42 PM
MARTIN JOHN CExecutive ChairmanMay 01Sale68.3173,3335,009,4293,126,636May 03 05:42 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffMay 01Sale68.315,000341,529112,988May 03 05:41 PM
MARTIN JOHN CExecutive ChairmanApr 03Option Exercise21.5873,3331,582,1593,199,969Apr 05 05:29 PM
MARTIN JOHN CExecutive ChairmanApr 03Sale67.1873,3334,926,2873,126,636Apr 05 05:29 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffMar 30Sale67.485,000337,392117,988Apr 03 06:23 PM
MARTIN JOHN CExecutive ChairmanMar 01Option Exercise21.5873,3331,582,1593,199,969Mar 03 06:29 PM
MOORE NICHOLAS GDirectorMar 01Option Exercise0.00173012,055Mar 03 06:03 PM
MARTIN JOHN CExecutive ChairmanMar 01Sale70.3873,3335,161,2063,126,636Mar 03 06:29 PM
WILSON GAYLE EDirectorFeb 23Option Exercise20.7133,350690,512140,836Feb 27 06:29 PM
MILLIGAN JOHN FPresident and CEOFeb 23Option Exercise21.58100,0002,157,5001,165,924Feb 27 06:13 PM
WILSON GAYLE EDirectorFeb 23Sale69.3020,3651,411,374120,471Feb 27 06:29 PM
YOUNG KEVINChief Operating OfficerFeb 10Option Exercise0.0090802,883Feb 14 12:53 PM
MARTIN JOHN CExecutive ChairmanFeb 01Option Exercise21.5873,3331,582,1593,204,429Feb 03 05:25 PM
YOUNG KEVINChief Operating OfficerFeb 01Option Exercise0.0062002,190Feb 03 05:32 PM
MARTIN JOHN CExecutive ChairmanFeb 01Sale72.5773,3335,322,0693,131,096Feb 03 05:25 PM
MARTIN JOHN CExecutive ChairmanJan 03Option Exercise21.5873,3371,582,2463,204,433Jan 05 03:39 PM
MARTIN JOHN CExecutive ChairmanJan 03Sale73.5973,3375,396,9713,131,096Jan 05 03:39 PM
MARTIN JOHN CExecutive ChairmanDec 01Option Exercise16.40100,0001,639,5003,231,096Dec 05 12:54 PM
WILSON GAYLE EDirectorDec 01Option Exercise0.002,1470107,486Dec 05 07:59 PM
MARTIN JOHN CExecutive ChairmanDec 01Sale73.33100,0007,332,8703,131,096Dec 05 12:54 PM
MADIGAN JOHN WDirectorNov 18Option Exercise20.71105,0002,174,025121,761Nov 22 02:45 PM
MADIGAN JOHN WDirectorNov 18Sale74.86105,0007,860,05916,761Nov 22 02:45 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffNov 09Sale79.0010,000790,000122,964Nov 14 01:03 PM
MARTIN JOHN CExecutive ChairmanNov 01Option Exercise16.40100,0001,639,5003,231,096Nov 03 06:10 PM
MARTIN JOHN CExecutive ChairmanNov 01Sale73.76100,0007,376,0463,131,096Nov 03 06:10 PM
MARTIN JOHN CExecutive ChairmanOct 03Option Exercise16.40100,0001,639,5003,231,096Oct 05 12:52 PM
MARTIN JOHN CExecutive ChairmanOct 03Sale77.63100,0007,762,9613,131,096Oct 05 12:52 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffSep 22Sale81.845,000409,220132,964Sep 26 04:54 PM
MILLIGAN JOHN FPresident and CEOSep 06Option Exercise20.7470,0001,451,8001,128,963Sep 08 01:35 PM
MILLIGAN JOHN FPresident and CEOSep 06Sale77.7470,0005,442,0801,058,963Sep 08 01:35 PM
MARTIN JOHN CExecutive ChairmanSep 01Option Exercise16.40100,0001,639,5003,231,096Sep 06 02:40 PM
MARTIN JOHN CExecutive ChairmanSep 01Sale77.48100,0007,748,3633,131,096Sep 06 02:40 PM
Lofton Kevin EDirectorAug 24Sale81.973,500286,8990Aug 25 05:05 PM
Carter Paul RutherfordEVP Commercial OpsAug 01Option Exercise39.132,00078,25564,305Aug 03 04:48 PM
MARTIN JOHN CExecutive ChairmanAug 01Option Exercise16.40100,0001,639,5004,119,727Aug 03 04:51 PM
MILLIGAN JOHN FPresident and CEOAug 01Option Exercise20.7470,0001,451,8001,128,963Aug 03 04:53 PM
MILLIGAN JOHN FPresident and CEOAug 01Sale70.9470,0004,965,5901,058,963Aug 03 04:53 PM
MARTIN JOHN CExecutive ChairmanAug 01Sale80.50100,0008,049,7854,019,727Aug 03 04:51 PM
Carter Paul RutherfordEVP Commercial OpsAug 01Sale79.812,000159,62062,305Aug 03 04:48 PM
Carter Paul RutherfordEVP Commercial OpsJul 31Option Exercise0.002,500063,622Aug 02 04:43 PM
MILLIGAN JOHN FPresident and CEOJul 05Option Exercise16.40112,0001,836,2401,170,963Jul 07 02:50 PM
MILLIGAN JOHN FPresident and CEOJul 05Sale84.33112,0009,444,9211,058,963Jul 07 02:50 PM
Carter Paul RutherfordEVP Commercial OpsJul 01Option Exercise24.912,00049,81063,122Jul 06 01:26 PM
MARTIN JOHN CExecutive ChairmanJul 01Option Exercise16.40100,0001,639,5004,119,727Jul 06 01:28 PM
MARTIN JOHN CExecutive ChairmanJul 01Sale84.73100,0008,472,5234,019,727Jul 06 01:28 PM
Carter Paul RutherfordEVP Commercial OpsJul 01Sale83.122,000166,25061,122Jul 06 01:26 PM
MILLIGAN JOHN FPresident and CEOJun 06Option Exercise16.40112,0001,836,2401,170,963Jun 08 06:59 PM
MILLIGAN JOHN FPresident and CEOJun 06Sale86.94112,0009,736,7791,058,963Jun 08 06:59 PM
Carter Paul RutherfordEVP Commercial OpsJun 01Option Exercise24.912,00049,81063,122Jun 03 04:46 PM
MARTIN JOHN CExecutive ChairmanJun 01Option Exercise16.40100,0001,639,5004,119,727Jun 03 04:51 PM
MARTIN JOHN CExecutive ChairmanJun 01Sale86.72100,0008,671,9504,019,727Jun 03 04:51 PM
Carter Paul RutherfordEVP Commercial OpsJun 01Sale87.022,000174,04061,122Jun 03 04:46 PM
Carter Paul RutherfordEVP Commercial OpsMay 31Option Exercise33.8857,0921,934,021118,214Jun 02 04:35 PM
Carter Paul RutherfordEVP Commercial OpsMay 31Sale86.8557,0924,958,60061,122Jun 02 04:35 PM